Published in PLoS One on June 25, 2015
Links of Autophagy Dysfunction to Inflammatory Bowel Disease Onset. Dig Dis (2016) 0.80
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature (2009) 19.18
Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science (2006) 18.74
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 11.39
Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 11.24
Autophagy and the integrated stress response. Mol Cell (2010) 11.21
Resolution of inflammation: the beginning programs the end. Nat Immunol (2005) 9.81
Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem (2002) 6.16
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev (1998) 4.50
Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr (2005) 3.86
Inflammation 2010: new adventures of an old flame. Cell (2010) 3.05
Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem (2001) 2.94
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol (2011) 2.19
Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem (2007) 2.06
Mycobacterial lipoprotein activates autophagy via TLR2/1/CD14 and a functional vitamin D receptor signalling. Cell Microbiol (2010) 1.62
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr (2011) 1.44
Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J Biol Chem (2007) 1.37
Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother (2002) 1.15
Polyphenols and health: update and perspectives. Arch Biochem Biophys (2010) 1.15
Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol (2005) 1.15
Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut (2006) 1.03
Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Mol Cancer Ther (2008) 0.98
Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J Biol Chem (2013) 0.96
Characterization of the gastrointestinal microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis (2011) 0.92
Polyphenols and health: what compounds are involved? Nutr Metab Cardiovasc Dis (2009) 0.90
Genes and 'in-vironment': how will our concepts on the pathophysiology of inflammatory bowel disease develop in the future? Dig Dis (2013) 0.87
Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines. Inflamm Bowel Dis (2010) 0.83
Anti-inflammatory activity of fruit fractions in vitro, mediated through toll-like receptor 4 and 2 in the context of inflammatory bowel disease. Nutrients (2014) 0.82
Autophagy is required for toll-like receptor-mediated interleukin-8 production in intestinal epithelial cells. Int J Mol Med (2011) 0.82
Selective degradation of the IkappaB kinase (IKK) by autophagy. Cell Res (2006) 0.81
Managing the risks of IBD therapy. Curr Gastroenterol Rep (2009) 0.79
Risks and benefits of biologic therapy for IBD. J Pediatr Gastroenterol Nutr (2009) 0.79